Main content

    Liver Transplant / Hepatology / Hepatitis / Liver Failure Clinical Trials

    Liver Disease Management & Transplant Program

    Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov




    Cirrhosis / Portal Hypertension
     |  Hepatitis B  |  Fatty Liver Disease (nonalcoholic steatohepatitis)  |  Hepatitis C  |  HCV with Renal Insufficiency  |  Co-infection (HCV & HIV)  |  Drug and CAM Induced Liver Injury  |  Thrombocytopenia  |  Liver Cancer - Hepatocellular Carcinoma (HCC)


    Active Trials


    Cirrhosis / Portal Hypertension

    Ascites

    Title: A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites
    Description: The study is a multi-center, prospective, open label, uncontrolled feasibility study enrolling 30 patients with refractory or recurrent ascites and cirrhosis at up to 6 sites. Patients will be enrolled during a 6 month enrollment phase after which data will be collected for 12 months with an initial analysis after 3 months. Extended follow-up for safety monitoring purposes will continue for the lifetime of the patient or until the device is explanted.
    Investigator: Todd Frederick, MD
    Eligibility: Subjects 21 years of age and older with a recurrence of grade 3 ascites requiring paracentesis for symptom relief more frequently than once per month for a minimum of 2 of the prior 3 months, cirrhosis of any etiology and failure to respond to or intolerance to high dose diuretics.
    Status: Active and open to enrollment
    Contact: Douglas Troyer, RN, 415-600-1369, Email: TroyerD@cpmcri.org about Study MOSAIC

    Hepatic Encephalopathy

    Title: Multicenter, Randomized Phase 2B Study Evaluating Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Cirrhotic Patients With Associated Hyperammonemia and an Episode of Hepatic Encephalopathy STOP-HE Study
    Description: The purpose of this study is to determine whether ornithine phenylacetate can speed recovery from an acute hepatic encephalopathy episode requiring hospitalization in cirrhotic patients
    Investigator: Todd Frederick, MD
    Eligibility: Subjects, 18 y/o and older, who are hospitalized with an acute episode of hepatic encephalopathy as complication of cirrhosis
    Status: Active and open to enrollment
    Contact: Douglas Troyer, RN, 415-600-1369, Email: TroyerD@cpmcri.org about Study Ocera STOP-HE

    Back to top

    Hepatitis B

    Title: Observational Study of Persons With Hepatitis B Virus Infection in North America (Cohort Study)
    Description: this study is to describe participants with hepatitis B virus (HBV) infection and identify factors that may cause the disease to activate or worsen
    Investigator: Stewart Cooper, MD
    Eligibility: Subjects 18 years and older with chronic hepatitis B infection
    Status: Active and open to enrollment
    Contact: Veronika Podolskaya, 415-600-1102, Email: PodolsV@cpmcri.org about Study Cohort

    Back to top

    Fatty Liver Disease (nonalcoholic steatohepatitis)

    Title:Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (Regenerate)
    Description: The primary objective of this study is to evaluate the effect of Obeticholic Acid treatment compared to placebo on liver-related clinical outcomes in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis.
    Investigator: Raphael Merriman, MD
    Eligibility: Subjects 18 years of age and older with Histologic evidence of NASH following a liver biopsy obtained no more than 6 months before Day 1 and histologic evidence of fibrosis stage 1, stage 2 or stage 3.
    Status: Active and open to enrollment
    Contact: Douglas Troyer, RN, 415-600-1369, Email: TroyerD@cpmcri.org about Study Regenerate

    Back to top

    Hepatitis C

    Title: A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)
    Description: The purpose of this study is to evaluate the safety and efficacy of ABT-493 and ABT-530 (or ABT-493/ABT-530) coadministered with and without ribavirin in adults with chronic HCV genotypes 2, 3, 4, 5 or 6 infection
    Investigator: Maurizio Bonacini, MD
    Eligibility: Subjects, 18 y/o and older, with screening laboratory result indicating HCV Genotype 2, 3, 4, 5, or 6 infection, chronic HCV infection and must be either HCV treatment-naïve or treatment-experienced. Subject must be documented as non-cirrhotic or as having compensated cirrhosis (GT3 only)
    Status: Active and open to enrollment
    Contact: Juliana Ma, 415-600-1368, Email: MaJX@cpmcri.org about Study Abbvie 868

    Title: An Open-Label, Multicenter Study to Evaluate Long-term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II)
    Description: The purpose of this study is to evaluate Long-term Outcomes following treatment with ABT-450/r/ABT-267, ABT-333 with or without RBV in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
    Investigator: Maurizio Bonacini, MD
    Eligibility: Subjects 18 years of age and older with chronic hepatitis C, genotype 1-infection (HCV RNA level greater than 1,000 IU/mL at screening)
    Status: Closed to enrollment
    Contact: Juliana Ma, 415-600-1368, Email: MaJX@cpmcri.org about Study TOPAZ II

    Back to top

    HCV with Renal Insufficiency

    Title: A Phase 2b, Open-Label Study of 200 mg or 400 mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 HCV-Infected Subjects With Renal Insufficiency
    Description: This study will evaluate the safety, tolerability and antiviral efficacy of sofosbuvir with ribavirin (RBV) in participants with genotype 1 or 3 hepatitis C virus (HCV) infection who have chronic renal insufficiency
    Investigator: Maurizio Bonacini, MD
    Eligibility: Subjects 18 years and older with a chronic genotype 1 or 3 HCV infection and HCV RNA ≥ 10^4 IU/mL at screening
    Status: Active and open to enrollment
    Contact: Juliana Ma, 415-600-1368, Email: MaJX@cpmcri.org about Study GS-US-334-0154

    Back to top

    Co-infection (HCV & HIV)


    Currently there are no Clinical Research Studies for HCV and HIV Co-infection. Please check back at a later date as we are always adding new studies.

    Back to top

    Drug and CAM Induced Liver Injury


    Currently there are no Clinical Research Studies for Drug and CAM Induced Liver Injury. Please check back at a later date as we are always adding new studies.

    Back to top

    Thrombocytopenia


    Currently there are no Clinical Research Studies for Thrombocytopenia. Please check back at a later date as we are always adding new studies.

    Back to top

    Liver Cancer - Hepatocellular Carcinoma (HCC)

    Please click here to see our Liver Cancer clinical trials.


    • updated March 2016

    Back to top